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Abstract
We present a new method for the detection of gene pathways associated with a multi-
variate quantitative trait, and use it to identify causal pathways associated with an imaging
endophenotype characteristic of longitudinal structural change in the brains of patients with
Alzheimer’s disease (AD). Our method, known as pathways sparse reduced-rank regression
(PsRRR), uses group lasso penalised regression to jointly model the effects of genome-wide
single nucleotide polymorphisms (SNPs), grouped into functional pathways using prior knowl-
edge of gene-gene interactions. Pathways are ranked in order of importance using a resam-
pling strategy that exploits finite sample variability. Our application study uses whole genome
scans and MR images from 464 subjects in the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database. 66,182 SNPs are mapped to 185 gene pathways from the KEGG pathways
database. Voxel-wise imaging signatures characteristic of AD are obtained by analysing 3D
patterns of structural change at 6, 12 and 24 months relative to baseline. High-ranking, AD
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endophenotype-associated pathways in our study include those describing chemokine, Jak-
stat and insulin signalling pathways, and tight junction interactions. All of these have been
previously implicated in AD biology. In a secondary analysis, we investigate SNPs and genes
that may be driving pathway selection, and identify a number of previously validated AD
genes including CR1, APOE and TOMM40.
Keywords: Alzheimer’s Disease, imaging genetics, atrophy, gene pathways, sparse regression
1 Introduction
A growing list of genetic variants have now been associated with greater susceptibility to develop
early and late-onset Alzheimer’s disease (AD), with the APOE4 allele consistently identified as
having the greatest effect (for an up to date list see www.alzgene.org). Recently, case-control sus-
ceptibility studies have been augmented by studies using neuroimaging phenotypes. The rationale
here is that the use of heritable imaging signatures (‘endophenotypes’) of disease may increase
the power to detect causal variants, since gene effects are expected to be more penetrant at this
level (Meyer-Lindenberg and Weinberger, 2006). This ‘imaging-genetic’ approach has been used to
identify genes associated with a range of imaging phenotypes including measures of hippocampal
volume (Stein et al., 2012) and cortical thickness (Burggren et al., 2008).
AD is a moderate to highly heritable condition, yet as with many common heritable diseases,
association studies have to date identified gene variants explaining only a relatively modest amount
of known AD heritability (Braskie et al., 2011). One approach to uncovering this ‘missing heri-
tability’ is motivated by the observation that in many cases disease states are likely to be driven
by multiple genetic variants of small to moderate effect, mediated through their interaction in
molecular networks or pathways, rather than by the effects of a few, highly penetrant mutations
(Schadt, 2009). Where this assumption holds, the hope is that by considering the joint effects
of multiple variants acting in concert, pathways genome-wide association studies (PGWAS) will
reveal aspects of a disease’s genetic architecture that would otherwise be missed when considering
variants individually (Wang et al., 2010; Fridley and Biernacka, 2011). Another potential benefit
of the PGWAS approach is that it can help to elucidate the mechanisms of disease by providing a
biological interpretation of association results (Cantor et al., 2010). In the case of AD for example,
an understanding of the underlying mechanisms by which gene mutations impact disease etiology
may play an important role in the translation of basic AD biology into therapy and patient care
(Sleegers et al., 2010).
In this paper, we present the first PGWAS method that is able to accommodate a multivari-
ate quantitative phenotype, and apply our method to a pathways analysis of the ADNI cohort,
comparing genome-wide single nucleotide polymorphism (SNP) data with voxel-wise tensor-based
morphometry (TBM) maps describing longitudinal structural changes that are characteristic of
AD. In this study we map SNPs to pathways from the KEGG pathways database, a curated
collection of functional gene pathways representing current knowledge of molecular interaction
and reaction networks (http://www.genome.jp/kegg/pathway.html). Our method is however
able to accommodate alternative sources of information for the grouping of SNPs and genes, for
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example using gene ontology (GO) terms, or information from protein interaction networks (Wu
et al., 2010; Jensen and Bork, 2010).
Many existing PGWAS methods, such as GenGen (Wang et al., 2009) and ALLIGATOR (Hol-
mans et al., 2009) rely on univariate statistics of association, whereby each SNP in the study is first
independently tested for association with a univariate quantitative or dichotomous (case-control)
phenotype. SNPs are assigned to pathways by mapping them to adjacent genes within a specified
distance, and individual SNP or gene statistics are then combined across each pathway to give a
measure of pathway significance, corrected for multiple testing. Methods must also account for
the potentially biasing effects of gene and pathway size and linkage disequilibrium (LD), and this
is generally done through permutation. A potential disadvantage of these methods is that each
SNP is considered separately at the first step, with no account taken of SNP-SNP dependencies.
In contrast, a multilocus or multivariate model that considers all SNPs simultaneously may char-
acterise SNP effects more accurately by aiding the identification of weak signals while diminishing
the importance of false ones (Hoggart et al., 2008).
In earlier work we developed a multivariate PGWAS method for identifying pathways asso-
ciated with a single quantitative trait (Silver and Montana, 2012). We used a sparse regression
model - the group lasso - with SNPs grouped into pathways. We demonstrated in simulation stud-
ies using real SNP and pathway data, that our method showed high sensitivity and specificity for
the detection of important pathways, when compared with an alternative pathways method based
on univariate SNP statistics. Our method showed the greatest relative gains in performance where
marginal SNP effect sizes are small. Here we extend our previous model to accommodate the case
of a multivariate neuroimaging phenotype. We do this by incorporating a group sparsity constraint
on genotype coefficients in a multivariate sparse reduced-rank regression model, previously devel-
oped for the identification of single causal variants (Vounou et al., 2010). Our proposed ‘Pathways
Sparse Reduced-Rank Regression’ (PsRRR) algorithm incorporates phenotypes and genotypes in
a single model, and accounts for potential biasing factors such as dependencies between voxels and
SNPs using an adaptive, weight-tuning procedure.
The article is presented as follows. We begin in section 2.1 with a description of the voxel-
wise TBM maps used in the study, and in section 2.2 we outline how we use these maps to
generate an imaging signature characteristic of structural change in AD, that is able to discriminate
between AD patients and controls. In section 2.3 we describe the genotype data used in the study,
together with quality control procedures, and in section 2.4 we explain how this genotype data is
mapped to gene pathways. The theoretical underpinnings of the PsRRR method are described in
section 2.5. We explain our method for ranking AD-associated pathways, SNPs and genes using
a resampling procedure in section 2.6, and discuss our strategies for addressing the significant
computational challenge of fitting a regression-based model with such high dimensional datasets
in section 2.7. Pathway, SNP and gene ranking results are presented in section 3, and we conclude
with a discussion in section 4.
2 Materials and methods
Imaging and genotype data used in this study were obtained from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) database (adni.loni.ucla.edu). The ADNI was launched in 2003 by
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the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengi-
neering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies
and non-profit organizations, as a 5-year public-private partnership. The primary goal of ADNI
has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography
(PET), other biological markers, and clinical and neuropsychological assessment can be combined
to measure the progression of mild cognitive impairment (MCI) and early AD. Determination
of sensitive and specific markers of very early AD progression is intended to aid researchers and
clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and
cost of clinical trials.
2.1 Imaging data
Longitudinal brain MRI scans (1.5 Tesla) were downloaded from the ADNI public database (http:
//www.loni.ucla.edu/ADNI/Data/). Serial brain MRI scans (N=3512; see Table 1) were analyzed
from 200 probable AD patients, 410 individuals with amnestic MCI, and 232 healthy elderly
controls (CN). Subjects were scanned at screening and followed up at 6, 12, 18, 24, 36, and 48
months. All subjects were scanned with a standardized 1.5T MP-RAGE protocol developed for
ADNI (Jack et al., 2008). The typical acquisition parameters were repetition time (TR) of 2400
ms, minimum full echo time (TE), inversion time (TI) of 1000 ms, flip angle of 8, 24 cm field of
view, 192× 192× 166 acquisition matrix in the x−, y−, and z− dimensions, yielding a voxel size
of 1.25 × 1.25 × 1.2 mm3, later reconstructed to 1 mm isotropic voxels. Image correction steps
included gradwarp (Jovicich et al., 2006), B1-correction (Jack et al., 2008), N3 bias field correction
(Sled et al., 1998), and phantom-based geometrical scaling (Gunter et al., 2006).
Linear registration (9-parameter) was used to align the longitudinal scan series of each subject
and then the mutually aligned time-series was registered to the International Consortium for Brain
Mapping template (ICBM-53) (Mazziotta et al., 2001). Brain masks that excluded skull, other
non-brain tissues, and the image background were generated automatically using a parameter-less
robust brain extraction tool (ROBEX) (Iglesias et al., 2011).
Individual Jacobian maps were created to estimate 3D patterns of structural brain change
over time by warping the skull-stripped, globally registered and scaled follow-up scan to match
the corresponding screening scan. We used a non-linear, inverse consistent, elastic intensity-
based registration algorithm (Leow et al., 2005), which optimizes a joint cost function based on
mutual information (MI) and the elastic energy of the deformation. Color-coded maps of the
Jacobian determinants were created to illustrate regions of ventricular/CSF expansion (i.e., with
det J(r) > 1), or brain tissue loss (i.e., with det J(r) < 1) (Ashburner and Friston, 2003; Chung
et al., 2001; Freeborough and Fox, 1998; Riddle et al., 2004; Thompson et al., 2000; Toga, 1999)
over time. These longitudinal maps of tissue change were also spatially normalized across subjects
by nonlinearly aligning all individual Jacobian maps to an average group template known as the
minimal deformation target (MDT), for regional comparisons and group statistical analyses.
The study was conducted according to the Good Clinical Practice guidelines, the Declaration
of Helsinki and U.S. 21 CFR Part 50-Protection of Human Subjects, and Part 56-Institutional
Review Boards. Written informed consent was obtained from all participants before experimental
procedures, including cognitive tests, were performed.
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Table 1: Available scans for the ADNI-1 dataset (downloaded on February 28, 2011)
Screening 6Mo 12Mo 18Mo 24Mo 36Mo 48Mo
AD 200 165 144 n/a 111 n/a n/a
MCI 410 358 338 296 253 176 41
CN 232 214 202 n/a 178 149 45
Total 842 737 684 296 542 325 86
At screening:
Group age (years) N male N female
AD 75.7±7.7 103 97
MCI 74.8±7.5 264 146
CN 76.0±5.0 120 112
2.2 Voxel filtering
To maximise the power to detect causal pathways, we seek a phenotype which is highly represen-
tative of those structural changes in the brain that are characteristic of AD. One approach is to
use prior knowledge on regions of interest (ROI) to extract a univariate quantitative measure as
a disease signature (Potkin et al., 2009). We instead use a voxel-wise, data-driven approach to
produce a multivariate disease signature.
We begin by selecting 464 individuals (99 AD, 211 MCI, 154 CN) with longitudinal maps at
time points 6, 12 and 24 months, who have been genotyped by ADNI. Other time points are
excluded because of missing observations. For each voxel and for each one of the three groups, we
then fit a linear regression with an intercept term, where the dependent variable is the voxel value
(change relative to baseline at screening), and the independent variable is time. The regression
coefficient for the slope thus gives a summary measure of tissue change over time at each voxel. We
next perform an analysis of variance (ANOVA) on each slope coefficient to identify which voxels are
discriminative between AD and CN, with sex and age as covariates (MCI subjects are not used at
this stage as we wish to obtain a clear imaging-derived signature for AD). We then select the most
discriminative voxels whose ANOVA p-values exceed a level of 0.05, with a Bonferroni correction
for multiple testing. The final set of phenotypes used in the study correspond to the voxel-wise
slope coefficients for all 464 subjects (AD, MCI and CN) at the selected voxels, corrected for sex
and age.
2.3 Genotype data
Genotypes for the 464 subjects in the study were obtained from the ADNI database. ADNI
genotyping is performed using the Human610-Quad Bead-Chip, which includes 620,901 SNPs and
copy number variations (see Saykin et al. (2010) for details). SNPs defining the APOE4 variant are
not included in the original genotyping chip, but have been genotyped separately by ADNI. These
were added to the final genotype dataset. Subjects were unrelated, and all of European ancestry,
and passed screening for evidence of population stratification using the procedure described in
(Stein et al., 2010). We included only autosomal SNPs in the study, and additionally excluded
SNPs with a genotyping rate < 95%, a Hardy-Weinberg equilibrium p-value < 5 × 10−7, and a
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minor allele frequency < 0.1. Finally, since our method does not allow for missing SNP minor
allele counts, missing genotypes were imputed (see Vounou et al. (2011) for details). 434,271 SNPs
remained after all SNP filtering steps described above.
2.4 SNP to pathway mapping
Our SNP mapping procedure rests on the extraction of prior information from a pathways database
that provides curated lists of genes, mapped to functional networks or pathways. Pathways
databases such as those provided by KEGG (http://www.genome.jp/kegg/pathway.html), Re-
actome (http://www.reactome.org/) and Biocarta (http://www.biocarta.com/) typically clas-
sify pathways across a number of functional domains, for example apoptosis, cell adhesion or lipid
metabolism; or crystallise current knowledge on specific disease-related molecular reaction net-
works.
Starting with a list of all genes that map to at least one pathway in the database, we assign SNPs
to genes within a specified distance, upstream or downstream of the gene in question, and thence
to pathways. This process is illustrated schematically in Fig. 1. For our AD pathways study, we
Figure 1: Schematic illustration of the SNP to pathway mapping process. (i) Known genes (green circles)
are mapped to pathways using information on gene-gene interactions (top row), obtained from a gene
pathways database. Many genes do not map to any known pathway (unfilled circles). Also, some genes
may map to more than one pathway. (ii) Genes that map to a pathway are in turn mapped to genotyped
SNPs within a specified distance. Many SNPs cannot be mapped to a pathway since they do not map
to a mapped gene (unfilled squares). Note SNPs may map to more than one gene. Some SNPs (orange
squares) may map to more than one pathway, either because they map to multiple genes belonging to
different pathways, or because they map to a single gene that belongs to multiple pathways.
proceed as follows. A list of 21,004 human gene chromosomal locations, corresponding to human
genome assembly GRCH36 was obtained using Ensembl’s BIOMART API (www.biomart.org).
SNPs were then mapped to any gene within 10k base pairs, upstream or downstream of the
gene in question. This resulted in 211,106 SNPs being mapped to 18,405 genes. While the
majority of known genes did map to at least one SNP in our study, approximately half of the
SNPs passing QC were not located within 10kbp of a known gene. For pathway mapping, we used
the KEGG canonical pathway gene sets obtained from from the Molecular Signatures Database
v3.0 (http://www.broadinstitute.org/gsea/msigdb/index.jsp), which contains 186 gene sets,
which map to a total of 5,267 distinct genes, with many genes mapping to more than one pathway.
Note that only around 25% of all known genes map to a pathway in this dataset. We map all SNPs
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within 10kbp of one or more of the 5,267 pathway-mapped genes to the pathway(s) concerned.
Finally, we exclude the largest pathway, by number of mapped SNPs, (‘Pathways in Cancer’) that
is highly redundant, in that it contains multiple other pathways as subsets. This results in 66,162
SNPs mapped to 4,425 genes and 185 pathways (see Fig. 2).
Figure 2: Mapping SNPs to pathways
The distribution of pathway sizes in terms of the number of SNPs that they map to is illustrated
in Fig. 3 (left). Pathway sizes range from 57 to 5,111 SNPs (mean 949). The distribution of
overlapping SNPs, that is the number of pathways to which each SNP is mapped, is illustrated in
Fig. 3 (right). This ranges from 1 to 45 pathways (mean 2.65).
Note that following the above procedure, some genes previously implicated in AD studies do
not map to any pathways, and thus are not included in the analysis. For example, in this study, 12
out of 30 genes highlighted in the review by Braskie et al. (2011) are mapped to pathways. Also
note that since SNPs are mapped to all genes within a range of 10kbp, AD implicated SNPs may
map to more than one gene, and its corresponding pathway(s). This is the case for example with
a number of SNPs mapping to the APOE and TOMM40 genes. This information is summarised
in Table 2.
2.5 Pathways sparse reduced-rank regeression
We consider the problem of identifying gene pathways associated with a multivariate quantitative
trait (MQT) or phenotype, Y ∈ RQ. The observed values for phenotype q, measured for N
unrelated individuals, are arranged in an (N × 1) response vector yq, and the Q phenotypes are
arranged in an (N × Q) response matrix Y = (y1, . . . ,yQ). We assume minor allele counts for
P SNPs are recorded for all individuals, and denote by xij the minor allele count for SNP j on
individual i. These are arranged in an (N×P ) genotype design matrix X. We additionally assume
7
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Figure 3: Left : Pathway sizes. Distribution of KEGG pathways, by the number of ADNI SNPs that they
map to. Right : SNP overlaps. Distribution of ADNI SNPs, by the number of pathways that they map
to. SNPs map to multiple pathways either because they map to a gene that belongs to more than one
pathway, or because they map to more than one gene belonging to more than one pathway.
Table 2: AD genes included in this study. 12 out of 30 genes previously implicated with AD (Braskie
et al., 2011) that are included in this study are listed in the left hand column. These are genes that (a)
map to a KEGG pathway and (b) have a genotyped SNP within 10kbp. The right hand column shows
neighbouring genes that map to one or more SNPs mapping to the respective AD implicated gene.
Implicated gene Mapped genes in study
TOMM40 TOMM40 APOE PVRL2
ACE ACE
EPHA4 EPHA4
CCR2 CCR2 CCR5
APOE TOMM40 APOE PVRL2
FAS FAS
CHRNB2 ADAR CHRNB2
EFNA5 EFNA5
LDLR LDLR
CR1 CR1 CR2
GRIN2B GRIN2B
IL8 IL8
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all phenotypes and genotypes are mean centred, and that SNP genotypes are standardised to unit
variance, so that
∑
i x
2
ij = 1, for j = 1, . . . , P .
If we denote by C = (C1, . . . ,CQ), a (P × Q) matrix of regression coefficients, then we can
model the multivariate response as
(1) Y = XC + E
where E is an (N ×Q) matrix of error terms. A least squares estimate for C may be obtained by
generalising the multiple least squares optimisation to include a multivariate response, that is by
minimising the residual sum of squares
(2) MMMLR = Tr{(Y −XC)(Y −XC)′}.
Where N > P and the design matrix X is of full rank, the least squares estimates are given by
Cˆ = (X
′
X−1)X′Y. Note that the (P × 1) column vectors Cˆ1, . . . , CˆQ of Cˆ are just the least
squares estimates of the regression of each yq on X, that is
(3) Cˆq = arg min
Cq
||yq −XCq||22 q = 1, . . . , Q
where || · ||2 denotes the `2 (Euclidean) norm.
For high-dimensional datasets, such as those typically found in genomics, this model is unsuit-
able for a number of reasons. Firstly, P  N , so that X′X is singular and thus not invertible and
the estimates Cˆq are not uniquely defined. Even where P < N , for example in a candidate gene
study, LD or equivalently near multi-collinearity between predictors means that X′X is nearly
singular, resulting in inflated variance in SNP coefficient estimates. Furthermore, the estimation
(3) is equivalent to performing Q independent regressions, and takes no account of the multivariate
nature of Y. Ideally, we would like to exploit this in our estimation procedure to boost power
(Breiman and Friedman, 1997; Vounou et al., 2010).
These limitations are addressed in reduced-rank regression (RRR), (Reinsel and Velu, 1998;
Hastie et al., 2008), by restricting the rank of the coefficient matrix C. Specifically we impose the
constraint that C has rank r < min(P,Q), and rewrite C as C = BA, where A and B both have
(full) rank r. The reduced rank form of (1) is then given by
(4) Y = XBA + E
where B and A are (P × r) and (r×Q) matrices of regression coefficients respectively relating to
genotypes and phenotypes. This model has the interesting interpretation of exposing r hidden or
latent factors, which capture the major part of the relationship between Y and X. If we denote
by B(k), the kth column of B, then we see that the products XB(k), k = 1, . . . , r, represent r
linear combinations of the P predictor variables. Similarly, the r row vectors, A(k), k = 1, . . . , r,
represent the transformation of each of these back to the dimensions of Y, so that they can predict
the response. The linear combinations XB(k) and YA
′
(k) thus represent a reduced set of r (latent)
factors that capture the relationship between response and predictors, reduced in the sense that
this set has dimensionality r < min(P,Q).
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As a first approximation, we consider the rank-1 RRR model which captures the first set of
genotype and phenotype latent factors describing the association between X and Y. With r = 1,
we rewrite (4) as
(5) Y = Xba + E
where b and a are (P × 1) and (1×Q) coefficient vectors respectively relating to genotypes and
phenotypes. Least squares estimates for bˆ and aˆ are then obtained by minimising the rank-1
equivalent of (2),
(6) MRR1R = Tr{(Y −Xba)Γ(Y −Xba)′}
where Γ is a given (q × q) positive definite matrix of weights. The choice of Γ reflects how we
deal with correlation between the responses y1, . . . ,yq in the least squares optimisation. Such
correlations can be exploited by setting Γ to be the inverse of the estimated covariance of the
responses. In the context of imaging genetics for example, where a voxel-wise multivariate response
may be derived from structural MRI, spatial correlations between phenotypes are expected in
part to reflect common genetic variation. However, the calculation of the inverse (Y′Y)−1 is
computationally very intensive, so in common with Vounou et al. (2010), we instead use the
simplifying approximation Γ = Iq, effectively assuming the responses to be uncorrelated.
We now turn to the case where all P SNPs may be mapped to L groups, Gl ⊂ {1, . . . , P},
l = 1, . . . , L, for example by mapping SNPs to gene pathways (see section 2.4). We begin by
assuming that pathways are disjoint or non-overlapping, that is Gl ∩ Gl′ = ∅ for any l 6= l′. We
denote the rank-1 vector of SNP regression coefficients by b = (b1, . . . , bP ). We additionally
denote the matrix containing all SNPs mapped to pathway Gl by Xl = (Xl1 , Xl2 , . . . , XSl), where
Xj = (x1j , x2j , . . . , xNj)
′, is the column vector of observed SNP minor allele counts for SNP j, and
Sl is the number of SNPs in Gl. Finally, we denote the corresponding vector of SNP coefficients
by bl = (bl1 , bl2 , . . . , bSl).
In general, where P is large, we expect only a small proportion of SNPs to be ‘causal’, in
the sense that they exhibit phenotypic effects. We further assume that causal SNPs will tend
to be enriched within functional groups, or gene pathways. This latter assumption is illustrated
schematically in Fig. 4, where causal SNPs (marked in grey) tend to accumulate within a small
number of causal pathways, while the majority of pathways contain no causal SNPs. A model that
generates such a sparsity pattern is said to be group-sparse, in that SNPs affecting Y are to be
found in a set C ⊂ {1, . . . , L} of causal gene pathways (groups), with |C|  L, where |C| denotes
the cardinality of C. We seek a parsimonious model that is able to identify this set, C, of causal
pathways, by imposing a group-sparsity constraint on the estimated SNP coefficient vector, b.
In sparse reduced-rank regression (sRRR) (Vounou et al., 2010, 2011), sparse estimates for
genotype and/or phenotype coefficient vectors are obtained by imposing a regularisation penalty
on b and/or a respectively. Apart from the benefits of model parsimony, enforcing a sparsity
constraint on b also allows us to deal with the P  N case, and with multicollinearity between
predictors. In our proposed ‘Pathways Sparse Reduced-Rank Regression’ (PsRRR) model, the
required group sparsity pattern is obtained by imposing an additional group lasso penalty (Yuan
and Lin, 2006) on (6). Group-sparse solutions to the rank-1 RRR model (5) are then obtained by
10
Figure 4: Group-sparse distribution of causal SNPs. The set S ⊂ {1, . . . , P} of causal SNPs influencing
the phenotype are represented by boxes that are shaded grey. Causal SNPs are assumed to occur within
a set C of causal pathways. Here C = {2, 3}. Note that the particular distribution of causal SNPs may
vary for each individual, i = 1, . . . , N . The group sparsity assumption is that |C|  L.
minimising the following penalised least squares problem
(7) MPsRR1R =
1
2
Tr{(Y −Xba)(Y −Xba)′}+ λ
L∑
l=1
wl||bl||2
with respect to b and a. (7) corresponds to an ordinary least squares (OLS) optimisation, but
with an additional group-wise penalty whose size depends on ||bl||2, l = 1, . . . , L, a regularisation
parameter λ, and an additional group weighting parameter ωl that can vary from group to group.
Depending on the value of λ, this penalty has the effect of setting multiple pathway SNP coeffi-
cient vectors, bl = 0, l ⊂ {1, . . . , L}, thereby enforcing group sparsity. Pathways with non-zero
coefficient vectors form the set Cˆ of selected pathways, so that
Cˆ(λ) = {l : bl 6= 0}.
Expanding (7), and noting that the first term YY′ does not depend on b or a, solutions satisfy
(8) bˆ, aˆ = arg min
b,a
{1
2
(−2aY′Xb + aa′b′X′Xb) + λ
L∑
l=1
wl||bl||2
}
.
For fixed a, this penalised least squares problem equates to a convex optimisation in b, and is
thus amenable to solution using coordinate descent (Friedman et al., 2007). A global solution can
then be obtained by iteratively estimating one coefficient vector (b or a), while holding the other
fixed at its current value, until convergence (Chen and Chan, 2012).
Thus, for fixed b and λ, and with the additional constraint that bb′ = 1, we estimate aˆ as
aˆ = arg min
a
{1
2
(−2aY′Xb + aa′b′X′Xb) + λ
L∑
l=1
wl||bl||2
}
.
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Differentiating and setting to zero gives
aˆ =
b′X′Y
b′X′Xb
.
Similarly, for fixed a, and with the additional constraint that aa′ = 1, we have
(9) bˆ = arg min
b
{1
2
(−2aY′Xb + b′X′Xb) + λ
L∑
l=1
wl||bl||2
}
.
This is equivalent to a standard group lasso estimation problem with univariate response vector
Ya′. In earlier work we describe a method, ‘Pathways Group Lasso with Adaptive Weights’ (P-
GLAW), for solving this problem, specifically tailored to the situation where predictor variables
are SNPs grouped into pathways (Silver and Montana, 2012). Here, we briefly recap key points
of this method, and incorporate a number of extensions designed to accommodate a MQT in the
context of PsRRR with coordinate descent.
The minimising function (9) is convex, and can be solved using block coordinate descent (BCD)
(Friedman et al., 2010), an extension of coordinate descent to convex estimation with grouped
variables. BCD rests on obtaining successive estimates, bl, for each pathway in turn, while keeping
current estimates for all other pathways, bk, k 6= l, constant, until a global minimum is obtained.
For pathway Gl, l = 1, . . . , L, estimates for each SNP coefficient, bj , j = l1, . . . , lSl are obtained
through coordinate descent within the group. The group lasso estimation algorithm using BCD is
presented in Box 1.
Box 1 Ω(a,Y,X, λ): GL estimation algorithm using BCD
1. b← 0
block coordinate descent
2. repeat
3. for l = 1, 2, . . . , L
4. rl ← Ya′ −
∑
k 6=l Xkbk
5. if ||X′lrl||2 ≤ λwl
6. bl ← 0
7. else
coordinate descent within block
8. repeat
9. for j = l1, . . . , lSl
10. r← Ya′ −Xb
11. bj ← X
′
jr+bj
1+
λwl
||bl||2
12. until bl converges
13. until b converges
As λ increases, fewer groups (or pathways) are selected by the model (Box 1, step 5), while
for selected pathways with bl 6= 0, estimated SNP coefficients, bj , j = l1, . . . , Sl, tend to shrink
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towards zero (Box 1, step 11).
The full PsRRR estimation algorithm is presented in Box 2.
Box 2 Rank-1 PsRRR estimation algorithm using coordinate descent
1. a← 1/||1||2
2. repeat:
3. λ← γλmax, where λmax = minλ{λ : ||XTl Ya′||2 = λwl, l = 1, . . . , L}
4. b← Ω(a,Y,X, λ) (from Box 1)
5. b← b/||b||2 (normalise)
6. a← b′X′Yb′X′Xb
7. a← a/||a||2 (normalise)
8. until b and a converge
Note that we set the regularisation parameter, λ, to be a constant fraction (γ) of the maximal
value, λmax, where no groups are selected by the model.
A key feature of our P-GLAW method is the need to accommodate the fact that pathways
overlap, that is Gl ∩ Gl′ 6= ∅ for some l 6= l′, since SNPs may map to multiple pathways. To
enable the independent selection of pathways, we instead require that groups are disjoint (Jacob
et al., 2009). This is achieved through an expansion of the design matrix, X, formed from the
column-wise concatenation of the L sub-matrices of size (N × Sl), so that X = [X1,X2, . . . ,XL].
This expanded X has dimensions (N × P ∗), with P ∗ = ∑l Sl. A corresponding expansion of the
parameter vector, b = [b1
′,b2′, . . . ,bL′]′ is also required.
Another issue that we address is the problem of pathway selection bias, by which we mean the
tendency of the group lasso to favour the selection of specific pathways, under the null, where no
SNPs influence the phenotype. Such biases can arise for example from variations in the number
of SNPs or genes in pathways, and varying patterns of dependence (LD) between SNPs within
pathways. Under the null, with the regularisation parameter λ tuned so that a single pathway
is selected, pathway selection probabilities should follow a uniform distribution, namely with
probability Πl = 1/L, for l = 1, . . . , L. However, where biasing factors are present, the empirical
probability distribution, Π∗ will not be uniform. Our iterative weight tuning procedure works by
applying successive adjustments to the pathway weight vector, ω = (ω1, . . . , ωL), so as to reduce
the difference, dl = Π
∗
l (ω)−Πl, between the unbiased and empirical (biased) distributions for each
pathway. We begin with an initial weight vector, ω
(0)
l =
√
Sl, which corrects for the biasing effect
of group size in the group lasso model (Silver and Montana, 2012). At iteration τ , we compute
the empirical pathway selection probability distribution Π∗(ω(τ)) over multiple model fits with
permuted phenotypes, and compute dl for each pathway. We then apply the following weight
adjustment
w
(τ+1)
l = w
(τ)
l
[
1− sign(dl)(η − 1)L2d2l
]
0 < η < 1, l = 1, . . . , L
where the paramater η controls the maximum amount by which each wl can be reduced in a single
iteration, in the case that pathway Gl is selected with zero frequency. The square in the weight
adjustment factor ensures that large values of |dl| result in relatively large adjustments to wl.
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Iterations continue until convergence, where
∑L
l=1 |dl| < .
Even when relatively few SNPs or genes are associated with the phenotype, we can expect
multiple pathways to harbour genetic effects since many SNPs and genes overlap multiple path-
ways. Where more than one pathway is selected by the model, we therefore expect that pathway
selection probabilities will not be uniform, since the presence of overlapping SNPs means that
pathways are not independent. Instead, selection probabilities will reflect the pattern of overlaps
corresponding to the distribution of causal SNPs (or spurious associations under the null). This
non-uniform distribution of selection probabilities is to be expected and is in fact desirable, since
a signal corresponding to causal SNPs or genes should be captured in each and every pathway
that contains them. We have shown in extensive simulation studies, that where more than one
pathway is selected, the weight tuning process described above leads to substantial gains in both
sensitivity and specificity when identifying causal pathways (Silver and Montana, 2012).
Estimates for b and a respectively represent the first (rank 1) latent factors that are expected to
capture the strongest signal of association between gene pathways and the phenotype. In principle,
it is possible to capture further latent factors of diminishing importance, by iteratively repeating
the procedure described above, after regressing out the effects of previous factors (Vounou et al.,
2010). With PsRRR, the estimation of further ranks is complicated by the need to recalibrate the
group weights at each step, and by the typically large number of SNPs in selected pathways. For
this reason we consider only the first latent factor in this study.
2.6 Pathway, gene and SNP ranking
Pathway ranking
With most variable selection methods, a choice for the regularisation parameter, λ, must be made,
since this determines the number of variables selected by the model. Common strategies include the
use of cross validation to choose a λ value that minimises the prediction error between training and
test datasets (Hastie et al., 2008). One drawback of this approach is that it focuses on optimising
the size of the set, Cˆ, of selected pathways (more generally, selected variables) that minimises
the cross validated prediction error. Since the variables in Cˆ will vary across each fold of the
cross validation, this procedure is not in general a good means of establishing the importance of a
unique set of variables (Vounou et al., 2011). Alternative approaches, based on data resampling or
bootstrapping have been demonstrated to improve model consistency, in the sense that the ‘true’
variables are selected with a high probability (Bach, 2008; Meinshausen and Bu¨hlmann, 2010). We
adopt a resampling approach, in which we calculate pathway selection frequencies by repeatedly
fitting the model over B subsamples of the data, at a fixed value for λ. Selection frequencies
are expected to be relatively insensitive to the choice of λ, provided that it is small enough to
ensure that the set C of causal pathways is selected with a high probability at each subsample
(Meinshausen and Bu¨hlmann, 2010).
We denote the set of selected pathways at subsample b by
Cˆ(b) = {l : b(b)l 6= 0} b = 1, . . . , B
where b
(b)
l is the estimated SNP coefficient vector for pathway l at subsample b. The selection
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probability for pathway l measured across all B subsamples is then
pipathl =
1
B
B∑
b=1
I
(b)
l l = 1, . . . , L
where the indicator variable, I
(b)
l = 1 if l ∈ Cˆ(b), and 0 otherwise. Pathways are ranked in order
of their selection probabilities, pipathl1 ≥, . . . ,≥ pi
path
lL
.
SNP and gene ranking
The PsRRR model is designed to identify important pathways which may contain multiple genetic
markers with varying effect sizes. However, it is still interesting to establish which SNPs and genes
are most predictive of the response amongst those mapped to the set Cˆ(b) of selected pathways at
subsample b. Note that these are not necessarily the SNPs and genes that are driving the selection
of any particular pathway in the PsRRR model.
To rank SNPs and genes, we perform a second level of variable selection using sRRR with a
lasso penalty (Vounou et al., 2011). We first form the reduced (N × Z(b)) matrix XCˆ(b) , with
columns {Xj : j ∈
⋃
l∈Cˆ(b) Gl} corresponding to all SNPs in pathways selected at subsample b.
Sparse estimates for the corresponding SNP coefficient vector, β, and rank-1 phenotype vector α
then satisfy the equivalent of (8) with a lasso penalty, namely
βˆ, αˆ = arg min
β,α
{1
2
(−2αY′XCˆ(b)β +αα′β′X′Cˆ(b)XCˆ(b)β) + λ||β||1
}
.
We denote the set of SNPs selected at sample b by S(b), and further denote the set of selected
genes to which the SNPs in S(b) are mapped by φ(b) ⊂ Φ, where Φ = {1, . . . , G} is the set of gene
indices corresponding to all G mapped genes. Using the same strategy as for pathway ranking,
we obtain an expression for the selection probability of SNP j across B subsamples as
piSNPj =
1
B
B∑
b=1
I
(b)
j
where the indicator variable, I
(b)
j = 1 if j ∈ S(b), and 0 otherwise. A similar expression for the
selection probability for gene g is
pigeneg =
1
B
B∑
b=1
I(b)g
where the indicator variable, I
(b)
g = 1 if g ∈ φ(b), and 0 otherwise. SNPs and genes are then ranked
in order of their respective selection frequencies.
2.7 Computational Issues
All computer code is written in the open source Python programming language, using Numpy and
SciPy modules which are optimised for efficient operation with large matrices. Execution of the
PsRRR estimation algorithm nonetheless presents a considerable computational burden, both in
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terms of processor time and memory use. We therefore implement a number of strategies designed
to increase computational efficiency (see Silver and Montana (2012) for details). We use a Taylor
approximation of the group penalty that avoids the need for computationally intensive numerical
search methods (Breheny and Huang, 2009; Friedman et al., 2010). In addition, we use an ‘active
set’ strategy (Tibshirani et al., 2010; Roth and Fischer, 2008), that identifies a subset of pathways
that are more likely to be selected by the model at a given λ. Model estimation then proceeds
with this reduced set, followed by a final check to ensure that no other pathways should have
been included in the active set in the first place. Depending on the choice of λ, this can lead
to substantial gains in computational efficiency and a large reduction in memory requirements,
resulting from the very much reduced size of X in Ω(a,Y,X, λ).
The need to fit a large number of PsRRR models over multiple subsamples of the data for
pathway ranking presents another major computational bottleneck. However, the fact that each
subsample is generated entirely independently presents an opportunity for performing multiple
model fits in parallel. We implement such a strategy using a computer cluster, in which a single
client node distributes subsamples across 8 server nodes. Parallel computations and client-server
communication are implemented in Parallel Python (http://www.parallelpython.com/). The
reduction in computation time due to parallelisation is considerable. For example, in the AD
study described in this paper, total execution time (excluding weight tuning) with B = 1000
subsamples was 6 12 hours, whereas total execution time if each job were run separately would be
approximately 10 12 days.
3 Results
3.1 AD associated phenotypes
An imaging signature characteristic of AD was created using the procedure described in section
2.2. As described previously, we begin by computing a linear least-squares fit of the longitudinal
structural change across 3 time points at each voxel. An illustration of average slope coefficients,
and their variation between subjects, is shown in Fig. 5. Increased expansion of ventricular volumes
is clear in all subjects, but this increase is most marked in AD patients, where ventricular volumes
expand by an average 1.2% per year (white regions in left hand part of Fig. 5). AD patients also
show the most variation in structural change over time.
A statistical image showing the corresponding ANOVA p-values, a measure of the extent to
which each voxel is able to discriminate between ADs and CNs, is shown in the top row of Fig. 6.
From the Q∗ = 2, 153, 231 voxels in this image, we extract a final set of Q = 148, 023 voxels whose
p-values exceed a Bonferroni-corrected threshold of 0.05/Q∗. This final set of voxels that are most
discriminative between ADs and CNs, are highlighted in yellow in the bottom row of Fig. 6. These
Q voxels constitute the phenotype for each subject used in the study. We visualise the Euclidean
distances between subjects using the selected voxels in a 3D multi-dimensional scaling plot in
Fig. 7.
To verify the power of the set of selected voxels to discriminate between ADs and CNs, we
used a linear classifier, with Gaussian, class-conditional densities and common diagonal covariance
matrices. The performance of the linear classifier was assessed using 10-fold cross-validation, giving
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Figure 5: Sample mean (left) and standard deviation (right) of slope coefficients for the 3 subject groups.
Slope coefficients represent a linear approximation of change in brain volume over time. Scales represent
10× percentage change in voxel volume per year, so that for example a slope coefficient of 12 (white areas
in left hand plot) is equivalent to an average yearly increase in voxel volume of 1.2%.
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Figure 6: Imaging signature characteristic of AD. Top: Statistical image showing p-values (− log10 scale)
obtained from an ANOVA on the linear structural change over 3 time points, corrected for age and sex, to
discriminate between AD and CN subjects. Bottom: The final set of Q = 148, 023 selected voxels with p-
values exceeding a Bonferroni-corrected threshold αB = 0.05/2153231, (− log10 αB = 7.6) are highlighted
in yellow.
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Figure 7: 3D multi-dimensional scaling plot illustrating the spread of imaging signatures across ADs and
CNs. Imaging signatures correspond to selected voxels only.
figures for accuracy, sensitivity and specificity of 85.0%, 78.8% and 89.0%, respectively. While
optimisation of classification performance was not our primary concern, these figures compare
well with a range of high dimensional classification methods cited in the literature (Liu et al.,
2012; Cuingnet et al., 2011)
3.2 Pathway, SNP and gene rankings
We use the PsRRR algorithm described in section 2.5 to identify KEGG pathways associated with
the AD-discriminative longitudinal phenotypes described in the preceding section. Pathways are
ranked in order of importance using the pointwise stability selection method described in section
2.6, with B = 1000 subsamples. We use λ = 0.8λmax, which results in the selection of an average of
7 pathways at each subsample (min 1, max 15, SD = 2.3). Pathway ranking results are presented
in Table 3.
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Table 3: Top 30 pathways, ranked by pathway selection frequency.
Rank KEGG pathway name pipath Size Lasso selected genes in pathway1 Known AD genes2
(# SNPs) in pathway
1. Chemokine signaling pathway 0.261 2769 PRKCB PIK3R3 PIK3CG ADCY8 ADCY2 ITK GNAI1 XCL1 GNG2 GRK5 CCR2 IL8
2. Jak stat signaling pathway 0.234 1311 PIK3R3 PIK3CG IL2RA
3. Tight junction 0.227 3332 PRKCB PRKCA YES1 ACTN1 GNAI1 CTNNA2
4. Insulin signaling pathway 0.218 1517 PIK3R3 PIK3CG HK2 G6PC ACACA
5. Leukocyte transendothelial migration 0.213 2289 PRKCB PIK3R3 PRKCA PIK3CG ACTN1 ITK GNAI1 CTNNA2
6. Leishmania infection 0.204 620 CR1 PRKCB CR1
7. Calcium signaling pathway 0.202 5111 PRKCB PRKCA ADCY8 ADCY2 MYLK ATP2B2 RYR2 SLC8A1
8. Complement and coagulation cascades 0.184 783 CR1 CR1
9. Vibrio cholerae infection 0.174 831 PRKCB PRKCA KCNQ1
10. Cytokine cytokine receptor interaction 0.163 2267 XCL1 IL2RA FAS CCR2 IL8
11. Citrate cycle tca cycle 0.157 210
12. Focal adhesion 0.154 4009 PRKCB PIK3R3 PRKCA PIK3CG ACTN1 MYLK COL5A3
13. Alzheimers disease 0.138 2500 APOE APOE FAS GRIN2B
14. Arrhythmogenic right ventricular cardiomyopathy arvc 0.136 3229 ACTN1 RYR2 CTNNA2 SLC8A1
15. Phosphatidylinositol signaling system 0.133 2067 PRKCB PIK3R3 PRKCA PIK3CG DGKA DGKB DGKI
16. Small cell lung cancer 0.116 1610 PIK3R3 PIK3CG
17. Pyruvate metabolism 0.115 456 ACACA
18. Glycerophospholipid metabolism 0.113 1047 DGKA DGKB DGKI
19. Glycolysis gluconeogenesis 0.111 611 HK2 G6PC PFKP
20. Propanoate metabolism 0.108 471 ACACA
21. Fc gamma r mediated phagocytosis 0.102 1976 PRKCB PIK3R3 PRKCA PIK3CG
22. Huntingtons disease 0.100 1980 GRIN2B
23. Abc transporters 0.099 1701
24. Hematopoietic cell lineage 0.097 905 CR1 IL2RA CR1
25. Regulation of actin cytoskeleton 0.094 3371 PIK3R3 PIK3CG ACTN1 MYLK
26. Aldosterone regulated sodium reabsorption 0.091 744 PRKCB PIK3R3 PRKCA PIK3CG
27. Toll like receptor signaling pathway 0.091 712 PIK3R3 PIK3CG IL8
28. Proximal tubule bicarbonate reclamation 0.081 214
29. Melanogenesis 0.078 1638 PRKCB PRKCA ADCY8 ADCY2 GNAI1
30. Drug metabolism cytochrome p450 0.078 669
1Top 30 ranked genes in this pathway, using lasso selection (see Table 4). 2Previously identified AD genes in the pathway (see Table 2).
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SNPs and genes are ranked using sRRR with a lasso penalty on the SNP coefficient vector, as
described in section 2.6. Lasso selection is performed on pathways selected at each subsample in
the pathways analysis described above, so that once again B = 1000. The number of SNPs, Z(b),
included in the lasso model at subsample b varies according to the number and size (in terms of
the number of mapped SNPs) of selected pathways. Z(b) ranges from a minimum of 132, to a
maximum of 21,158 (mean = 9,835; SD = 3,729). As with pathway ranking, we use λ = 0.8λmax,
which results in the selection of an average of 13.1 SNPs at each subsample (min 1, max 75, SD
= 15.5).
Table 4: Top 30 SNPs and genes, respectively ranked by SNP and gene selection frequency, using lasso
sRRR. Note the APOE gene is selected at a lower frequency than the APO4 SNP, since in a significant
minority of subsamples the allele is selected in a pathway where it is mapped to the TOMM40 gene only.
SNP RANKING GENE RANKING
Rank SNP piSNP Mapped gene(s) Gene pigene # mapped SNPs
1 rs11118131 0.302 CR1 CR1 0.302 21
2 rs650877 0.302 CR1 PRKCB 0.284 73
3 rs12734030 0.302 CR1 PIK3R3 0.219 9
4 rs11117959 0.302 CR1 PRKCA 0.188 99
5 rs4788426 0.284 PRKCB PIK3CG 0.18 9
6 rs11074601 0.257 PRKCB YES1 0.171 11
7 rs677066 0.242 CR1 ADCY8 0.159 69
8 rs6691117 0.242 CR1 ADCY2 0.159 106
9 rs1052610 0.219 PIK3R3 HK2 0.148 28
10 APOE4 0.188 APOE, TOMM40 DGKA 0.139 3
11 rs4622543 0.188 PRKCA ACTN1 0.138 41
12 rs9896483 0.18 PRKCA APOE 0.138 4
13 rs4730205 0.18 PIK3CG ITK 0.125 27
14 rs12185470 0.171 YES1 GNAI1 0.122 22
15 rs12185469 0.171 YES1 XCL1 0.122 7
16 rs17516202 0.171 YES1 IL2RA 0.119 44
17 rs13189711 0.159 ADCY2 MYLK 0.117 24
18 rs263264 0.159 ADCY8 ATP2B2 0.111 135
19 rs680545 0.148 HK2 COL5A3 0.106 14
20 rs10876862 0.139 DGKA KCNQ1 0.103 118
21 rs772700 0.139 DGKA RYR2 0.098 190
22 rs4902672 0.138 ACTN1 CTNNA2 0.09 421
23 rs181455 0.13 ACTN1 GNG2 0.088 31
24 rs13184646 0.125 ITK G6PC 0.086 6
25 rs6973616 0.122 GNAI1 PFKP 0.084 51
26 rs2419114 0.122 XCL1 GRK5 0.084 56
27 rs942201 0.119 IL2RA DGKB 0.083 200
28 rs11256448 0.117 IL2RA SLC8A1 0.083 192
29 rs1107345 0.117 IL2RA ACACA 0.08 23
30 rs1254403 0.117 MYLK DGKI 0.078 49
We first consider the pathway ranking results in Table 3. Under the null, where there is
no association between phenotypes and genotypes, and with a single pathway selected by the
model at each subsample, the expected pathway selection frequency distribution is uniform, with,
pipathl = 1/185 ≈ 0.005. As explained in section 2.5, where more than one pathway is selected at
each subsample the selection frequency distribution will depend on the distribution of causal SNPs
and genes, and will not be uniform. For this reason, while we report pathway selection frequencies,
pipathl , the main focus is on pathway rankings. To aid interpretation of pathway rankings, for each
pathway, we list those genes in the pathway that are ranked in the top 30 genes, selected by lasso
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selection (in Table 4).
In the final column of Table 3 we list genes in the top ranked pathways that have previously
been linked to AD. Both the number of such genes affecting phenotypes in this study, and the
extent to which these genes may drive pathway selection are unknown. It is nevertheless interest-
ing to consider whether these genes are significantly enriched amongst high-ranking pathways. To
do this we calculate an average ranking for each ‘AD gene’ by taking the average rank achieved
by all pathways containing the gene in question. We then derive an AD gene enrichment score
by summing average AD gene ranks across all AD genes. A lower score thus indicates pathways
containing AD genes tend to be ranked high. We compare this empirically derived score with the
distribution of scores obtained by permuting pathway rankings 100,000 times. The null distribu-
tion of this enrichment score (obtained by permutation), and the empirically observed value are
compared in Fig. 8. Finally, we compute a p-value for the null hypothesis that the empirically
observed enrichment score has arisen by chance, as the proportion of enrichment scores obtained
through permutation that are lower than the observed value. This gives a value p = 0.0094.
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Figure 8: Measure of extent to which genes previously linked to AD are enriched in highly-ranked pathways.
The histogram shows the distribution of AD gene enrichment scores obtained when permuting pathway
rankings 100,000 times. The vertical black line indicates the observed AD gene enrichment score using
the true pathway rankings obtained in the study. From this we derive a p-value indicating the probability
that the empirical AD gene enrichment score could arise by chance as p = 0.0094. AD-linked genes are
those identified in Braskie et al. (2011).
4 Discussion
We describe a method for the identification of gene pathways associated with a multivariate
quantitative trait (MQT). Here, we extend previous work modelling a univariate response, where
we showed that a multivariate, group-sparse modelling approach can demonstrate increased power
to detect causal pathways, when compared to conventional approaches that begin by modelling
individual SNP-phenotype associations (Silver and Montana, 2012). We apply our method in an
AD gene pathways study using imaging endophenotypes, but our method is not restricted to the
case of biological pathways or imaging phenotypes, and can be applied to any data in which we
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seek to identify sparse groups of predictors affecting a multivariate response.
In any method modelling effects on an MQT, the use of a multivariate disease signature that
is characteristic of the disease under investigation is important. This is especially so in the case of
high-dimensional imaging phenotypes, where a poorly characterised imaging signature with low
signal to noise ratio may show no advantage over a simple ROI average-based approach (Vounou
et al., 2011). In this study we extract an AD imaging phenotype that is highly discriminative of
subjects with the disease, compared to controls.
Of the pathways identified as being associated with these AD endophenotypes (see Table 3),
functions associated with many of the top 10 ranked pathways have been linked to aspects of
AD biology described in the literature, including chemokine signalling, Jak stat signalling, tight
junction protein action, calcium and insulin signalling (Xia and Hyman, 1999; Kim et al., 2003;
Huber et al., 2001; de la Monte and Wands, 2005; Steen et al., 2005; Ravetti et al., 2010).
In order to better elucidate which genes may be driving pathway selection, we performed a
follow up analysis designed to identify SNPs and genes in selected pathways that are separately
associated with the phenotype (see Table 4). Since these gene (and associated SNP) rankings
are derived from lasso selection of all SNPs within selected pathways, irrespective of their ‘group’
structure within pathways, they are expected to capture larger, independent signals of association,
and not necessarily all the salient signals within a particular pathway that may be driving pathway
selection. In particular, the group lasso is designed to detect distributed signals that may not
be highlighted using lasso selection. From this analysis, it is clear that the lipid kinase genes
PIK3R3/PIK3CG, and the calcium-activated, phospholipid-dependent genes PRKCA/PRKCB
are important in driving selection of many pathways in the top 30 ranks. All these genes have
previously been linked in gene expression studies with β-amyloid plaque formation in the AD brain
(Liang et al., 2008). Aside from the validated AD risk gene CR1 (see below), other top-ranked
genes occurring more than once in the top 10 ranking pathways, include ADCY2 and GNAI1,
both of which have also been associated with AD in gene expression studies (Ravetti et al., 2010;
Taguchi et al., 2005).
Of particular note amongst top-ranking pathways is the citrate (tca) cycle, since this contains
no genes identified in the separate gene-ranking analysis. This suggests that selection of this
pathway might be driven by signals with distributed small effects, rather than signals with larger
marginal effects. Interestingly, this pathway is ranked first if the analysis is run selecting only a
single pathway at each subsample (data not shown). A number of studies have suggested links
between aberrations in the tca cycle and AD (Atamna and Frey, 2007).
Turning to the SNP and gene rankings in Table 4, the top ranking gene is the complement
component receptor gene CR1, and many of the top ranking SNPs also map to this gene. CR1
has been identified as one of the major AD risk genes (Lambert et al., 2009; Sleegers et al., 2010),
and has been associated with changes in hippocampal volume in AD (Biffi et al., 2010). As well as
the high-ranking PIK3R3/PIK3CG/PRKCA/PRKCB genes discussed above, the major AD risk
and phenotype-related gene APOE, and risk allele APOE4 are respectively ranked 10 and 12. In
our study the APOE gene maps to a single pathway, the KEGG Alzheimer’s disease pathway, and
this pathway is selected in ≈ 14% of subsamples. Notably, in all subsamples in which the KEGG
Alzheimer’s disease pathway is selected, the APOE4 allele is the sole selected SNP, confirming
the known large marginal effect of this allele on AD phenotypes. The fact that the Alzheimer’s
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disease pathway is not ranked higher may reflect the fact that selection of this pathway is driven by
the presence of this single, strong APOE4 signal, and as explained above, the model is designed
to identify distributed signals across a pathway. The slightly higher ranking of the APOE4 SNP,
relative to the APOE gene, reflects the fact that this SNP also maps to the TOMM40 gene, which
occurs in a number of other pathways selected by the model. The TOMM40 and APOE genes
are in LD, and there is evidence of their interaction in AD (Rajagopalan et al., 2012).
Our model rests on a number of assumptions, and as a consequence will fail to detect a
number of different association signals. For example, while our model implicitly accommodates
the fact that SNPs and genes interact within functional pathways, we do not explicitly model
interaction effects. Also, we make the simplifying assumption that voxel-wise measures of atrophy
are uncorrelated. In reality, the phenotype will exhibit a complex correlation structure which
will affect the association signal. Vounou et al. (2010) have demonstrated that even under this
simplifying assumption, significant gains in power can be achieved by modelling a multivariate
phenotype, compared to a mass univariate modelling approach. Finally, our model is founded on
the assumption that causal SNPs tend to accumulate within functional pathways, and as such
is not designed to identify significant marginal effects, as evidenced by its failure to rank the
high-risk APOE gene highly. For this last reason, any pathways analysis should be seen as being
complementary to conventional GWAS approaches.
This study also demonstrates some of the limitations of pathways studies in general. Many
genes previously implicated in AD do not map to known pathways in our study, so that these
genes and their associated SNPs, many of which are well validated, are excluded. This relative
sparsity of gene-pathway annotations reflects the fact that our understanding of how the majority
of genes functionally interact is at an early stage. As a consequence, annotations from different
pathways databases often vary (Soh et al., 2010), and in any case are undergoing rapid change.
Pathways studies also suffer from a lack of benchmark datasets to compare different methods,
and inevitably fail to capture the true complexity of dynamic interactions between pathways, by
taking a snapshot of a biological system at a given point in time (Khatri et al., 2012).
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